GlobeNewsWire
06 Nov 2025, 21:01 UTC · 49w ago
Teknova Reports Third Quarter 2025 Financial Results
Impact · against what's priced in
Teknova shows positive operational momentum with five consecutive quarters of revenue growth and a significantly narrowed adjusted EBITDA loss. While the Clinical Solutions segment is struggling due to biotech funding headwinds, the core Lab Essentials business is scaling effectively to offset those losses.
- TKNO+0.40
No priced-in read yet
- In context
The company achieved its fifth straight quarter of year-over-year growth and narrowed its adjusted EBITDA loss from negative $5.0 million to negative $1.6 million, signaling a trajectory toward profitability.
Read from the article alone
